Omaha NE 非小细胞肺癌临床试验
24项针对 非小细胞肺癌的研究正在 Omaha及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
招募中2 期
- Nebraska Cancer Specialists - Omaha - Wright Street /ID# 271527, Omaha
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
招募中3 期
- Nebraska Cancer Specialists/Oncology Hematology West PC - MECC, Omaha
- Nebraska Methodist Hospital, Omaha
- Nebraska Medicine-Village Pointe, Omaha
- 以及另外 3 项
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
招募中2 期
- Oncology Hematology West PC, Omaha
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
招募中1 期
- Exelixis Clinical Site #2, Omaha
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
招募中1/2 期
- Nebraska Cancer Specialists, Omaha
- XCancer, Omaha
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
招募中3 期
- Nebraska Medicine, Omaha
- Nebraska Medicine - Village Pointe, Omaha
- University Of Nebraska Medical Center, Omaha
- 以及另外 1 项
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
招募中3 期
- Oncology Hematology West P.C. dba Nebraska Cancer Specialists - Methodist, Omaha
- Oncology Hematology West, PC dba Nebraska Cancer Specialists - Bergan, Omaha
- Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
招募中3 期
- Research Site, Omaha
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
招募中2 期
- Research Site, Omaha
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
招募中2/3 期
- Local Institution - 007-590A, Omaha
- Local Institution - 007-590B, Omaha
- Nebraska Cancer Specialists - Midwest Cancer Center - Legacy, Omaha
- 以及另外 1 项
Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
招募中1 期
- Nebraska Cancer Specialists, Omaha
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
招募中1/2 期
- Nebraska Cancer Specialists, Omaha
A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer
招募中2 期
- University of Nebraska Medical Center, Omaha
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
招募中3 期
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
- Nebraska Medicine-Bellevue, Bellevue · 距离 9 英里
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
招募中2 期
- University of Nebraska Medical Center, Omaha
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
招募中1 期
- Nebraska Cancer Specialists - Omaha - Wright Street /ID# 247399, Omaha
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
招募中1 期
- Nebraska Cancer Specialists (Midwest Cancer Center - Legacy), Omaha
- XCancer Omaha / Urology Cancer Center, Omaha
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
招募中3 期
- Research Site, Omaha
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
招募中2 期
- University of Nebraska Medical Center, Omaha
Repositioning Immunotherapy in VetArans With Lung Cancer
招募中2 期
- Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE, Omaha
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
招募中1/2 期
- Nebraska Cancer Specialists, Omaha
GEMINI-NSCLC: NSCLC Biomarker Study
招募中观察性研究
- Nebraska Cancer Specialists, Omaha
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中观察性研究
- Massive Bio SYNERGY-AI site, Omaha
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
招募中1 期
- Nebraska Cancer Specialists, Omaha
其他城市的 非小细胞肺癌试验
- Houston, TX145 项研究
- New York City, NY121 项研究
- Arlington, VA104 项研究
- Nashville, TN97 项研究
- Boston, MA90 项研究
- Los Angeles, CA87 项研究
- St. Louis, MO73 项研究
- Chicago, IL61 项研究
- Baltimore, MD60 项研究
- San Antonio, TX59 项研究
- Columbus, OH57 项研究
- Washington, DC55 项研究
Omaha的其他研究
- 前列腺癌27 项研究
- 乳腺癌22 项研究
- 癌症（所有类型）18 项研究
- 结直肠癌18 项研究
- 多发性骨髓瘤16 项研究
- 卵巢癌14 项研究
- 非霍奇金淋巴瘤14 项研究
- 胰腺癌14 项研究
- 转移性癌症13 项研究
- 头颈鳞状细胞癌13 项研究
- 心力衰竭13 项研究
- 黑色素瘤12 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。